Verastem (VSTM) is in focus after releasing detailed TARGET-D 101 trial data for VS-7375 in KRAS G12D-mutated tumors and then quickly following up with a roughly US$250 million follow-on equity raise.

The TARGET-D 101 update and the roughly US$250 million equity raise arrived on top of an already strong run, with Verastem's 1-day share price return of 19.71% and 90-day share price return of 53.07% pointing to accelerating momentum. At the same time, the 1-year total shareholder return is slightly negative at 2.94% and the 5-year total shareholder return has declined 70.53%, leaving a mixed longer-term picture.

Pace your biotech exposure by scanning a curated set of 34 healthcare AI stocks that, like Verastem, hinge on clinical data and funding catalysts.

The stock now trades at a steep discount to analyst targets and implied fair value, even after this sharp move. Is that a bargain or a warning sign that the market's caution on Verastem is warranted?

Most Popular Narrative: 23% Undervalued

Verastem's most followed valuation story pegs fair value at $12 per share, above the last close of $9.23, and pins that gap on how the pipeline and losses are expected to evolve over time.

This narrative explores a more pessimistic perspective on Verastem compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts.

The bearish analysts are assuming Verastem's revenue will grow by 44.0% annually over the next 3 years.

See why 1 investors see Verastem as 23% undervalued .

The valuation work behind that fair value uses a 7.65% discount rate and assumes Verastem eventually reaches a profit margin in line with the wider US biotech group at 16.8%. To arrive at the $12 mark, the narrative expects revenue of $261.3 million and earnings of $43.9 million by around 2029, with the stock then trading on a P/E of 37.8x on those future profits.

That implies investors who agree with this framework are accepting a richer future earnings multiple than the current US Biotechs industry P/E of 17.4x in exchange for the growth profile described in the scenario. It also assumes share count increases of about 7% per year for the next three years, which reflects ongoing equity funding needs on the way to potential scale.

Result: Fair Value of $12 (UNDERVALUED)

Still, the Verastem story depends heavily on a single rare disease product and ongoing losses, so any trial setback or fresh equity raise could quickly challenge this undervalued thesis.

Find out about the key risks to this Verastem narrative .